POLYPEPTIDE GROUP AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.55 CHF | +2.43% |
|
+1.90% | +68.66% |
| 03-12 | PolyPeptide Group AG Provides Earnings Guidance for 2024 | CI |
| 03-12 | Transcript : PolyPeptide Group AG, 2023 Earnings Call, Mar 12, 2024 |
| Sales 2024 * | 349M 373M 341M 29.84B | Sales 2025 * | 407M 435M 398M 34.79B | Capitalization | 998M 1.07B 976M 85.38B |
|---|---|---|---|---|---|
| Net income 2024 * | -12M -12.85M -11.74M -1.03B | Net income 2025 * | 14M 14.99M 13.69M 1.2B | EV / Sales 2024 * | 3.13 x |
| Net Debt 2024 * | 93.91M 101M 91.85M 8.04B | Net Debt 2025 * | 132M 141M 129M 11.27B | EV / Sales 2025 * | 2.78 x |
| P/E ratio 2024 * |
-100
x | P/E ratio 2025 * |
64.5
x | Employees | 1,273 |
| Yield 2024 * |
-
| Yield 2025 * |
0.15% | Free-Float | 39.12% |
More Fundamentals
* Assessed data
More news
Latest transcript on PolyPeptide Group AG
More press releases
More news
| 1 day | +2.43% | ||
| 1 week | +1.90% | ||
| Current month | -2.48% | ||
| 1 month | -2.48% | ||
| 3 months | +85.73% | ||
| 6 months | +80.18% | ||
| Current year | +68.66% |
1 week
28.30
29.80
1 month
27.7530.65
Current year
14.1131.14
1 year
14.1131.14
3 years
14.11147.40
5 years
14.11147.40
10 years
14.11147.40
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 11/04/23 | |
| Chief Tech/Sci/R&D Officer | 52 | 31/12/11 | |
Jens Fricke
COO | Chief Operating Officer | 59 | 30/11/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 31/12/20 | |
Peter Wilden
CHM | Chairman | 67 | 31/03/21 |
Jane Anne Salik
BRD | Director/Board Member | 71 | 31/12/05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +2.14% | - | |
| 0.00% | 26 M€ | -4.26% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 29.55 | +2.43% | 23,502 |
| 25/04/24 | 28.85 | -1.87% | 17,393 |
| 24/04/24 | 29.4 | -1.01% | 18,164 |
| 23/04/24 | 29.7 | +5.13% | 33,736 |
| 22/04/24 | 28.25 | -2.59% | 32,780 |
Delayed Quote Swiss Exchange, April 26, 2024 at 04:31 pm
More quotes
Polypeptide Group AG is a Switzerland-based Contract Development & Manufacturing Organization (CDMO) focusing on proprietary and generic GMP-grade peptides used by pharmaceutical and biotech companies in approved pharmaceutical products, drugs in clinical development as well as in generic products.
Sector
Pharmaceuticals
Calendar
12/08/2024
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
30.26
EUR
Average target price
22.24
EUR
Spread / Average Target
-26.52%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +68.66% | 1.07B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- PPGN Stock
